Visual abstract | Neonatal and maternal outcomes in pregnant women with MPN: A population-based Swedish study

Among patients with newly diagnosed myeloproliferative neoplasms (MPN), 10–20% are of fertile age, and pregnancy in patients with MPN may pose fetal and maternal complications, such as maternal thrombosis, hemorrhage, and placental dysfunction.¹

The live birth rates in pregnant women with polycythemia vera or essential thrombocytosis are reported to be 65% and 70%, respectively.¹ Although prospective studies have reported a higher live birth rate in pregnant women with MPN, these studies have been limited by small patient numbers and further systematic studies are limited by the infrequent occurrence of pregnancies in such patients.¹

Here, we present a visual abstract representing the key findings from a large population-based study of pregnant women with MPN in Sweden and the associated neonatal and maternal adverse events, which were published by Landtblom, et al.¹ in Leukemia.